NEW YORK, Feb 13 – Ariad Pharmaceuticals received a patent for a method to control gene expression in humans and other animals, the company said Tuesday.
The technology uses small molecules to regulate the extent of gene activation. It is part of Ariad’s Argent gene regulation system, a gene regulation technology designed for high throughput analysis of in vitro and in vivo gene function, and " dose-dependent control” of gene and cell therapy products, Ariad said.
Ariad of Cambridge, Mass., which has developed several drug candidates based on its cellular regulation technology, is making newly-patented method and accompanying technology available for license, CEO Harvey Berger said in a statement.
Ariad said it has previously licensed its other gene regulation technologies to hundreds of academic institutions.